Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) is now available.
Shanghai Pharmaceuticals Holding Co., Ltd. has announced its Annual General Meeting scheduled for June 26, 2025, where several key proposals will be considered. These include the approval of the 2024 Annual Report, financial plans for 2025, profit distribution, re-appointment of the accounting firm, and issuance of corporate bonds, which could significantly impact the company’s financial strategy and stakeholder interests.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$15.70 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a joint stock company based in the People’s Republic of China, primarily engaged in the pharmaceutical industry. The company focuses on the production and distribution of pharmaceutical products and services, catering to a wide market within the healthcare sector.
Average Trading Volume: 5,337,783
Technical Sentiment Signal: Sell
Current Market Cap: HK$65.5B
Learn more about 2607 stock on TipRanks’ Stock Analysis page.